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Abstract Mice deficient in granulocyte-macrophage colony
stimulating factor (GM-CSF) develop pulmonary alveolar
proteinosis (PAP). We found that bronchoalveolar lavage fluid
(BALF) from 11 patients with idiopathic pulmonary alveolar
proteinosis (IPAP) suppressed the growth of peripheral blood
monocytes and TF-1 cells, a cell line dependent on either GM-
CSF or interleukin-3 (IL-3). The inhibitory effect of PAP-BALF
occurred only when TF-1 cells were cultured with GM-CSF but
not when cultured with IL-3, suggesting that PAP-BALF
contains a factor that specifically interferes with GM-CSF
function. 125I-GM-CSF binding to TF-1 cells was prevented in
the presence of BALF from IPAP patients. Furthermore, cross-
linking of 125I-GM-CSF to IPAP-BALF produced two major
bands on SDS-PAGE; these bands were not observed in normal
BALF. These data suggest that IPAP is caused by expression of
binding factor(s) which inhibit GM-CSF function in the lung.
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1. Introduction
Pulmonary alveolar proteinosis (PAP) is a rare disease that
causes progressive dyspnea. It is associated with intermittent
accumulation of excessive surfactant composed of phospholip-
ids and surfactant proteins designated SP-A, B, C, and D in
the alveoli and terminal bronchioli [1,2]. When these materials
are deposited in the alveoli, they block oxygen transport in the
lung and sometimes cause severe hypoxemia. Three forms of
PAP are known. The most common form is primary or idio-
pathic. A secondary form is associated with other diseases
such as pulmonary infection, hematological malignancies,
and inhalation of chemicals and minerals [3]. A congenital
form is associated with hereditary SP-B de¢ciency [4] or de-
fective expression of the common L chain of the granulocyte-
macrophage colony stimulating factor (GM-CSF) receptor [5].
The etiology of idiopathic PAP (IPAP) is unknown. Recent
clinical studies suggest that the disease is due to reduced clear-
ance rather than excessive secretion of surfactant [6]. Because
the bronchoalveolar lavage £uid (BALF) from PAP patients is
enriched in surfactant protein A, the clearance of SP-A may
be critically defective [7]. SP-A clearance is performed by al-
veolar macrophages (AM) and type II pneumocytes [8], which
led Claypool and colleagues to suggest that AM in PAP are
defective in surfactant processing or clearance [9]. Because
IPAP is e¡ectively treated by massive lavage [10], it is possible
that lavage removes substance(s) from the lung that interfere
with AM function.
Mice de¢cient in the gene for GM-CSF [11] or L chain of
GM-CSF receptor [12,13] develop a PAP-like disease with
alveolar accumulations of surfactant. These data demonstrate
that GM-CSF signaling is necessary for surfactant homeosta-
sis in the lung. The mouse model, therefore, raises the possi-
bility that GM-CSF is involved in the pathogenesis of human
PAP.
In this study we found that BALF from IPAP patients
strongly inhibits the growth of monocytes and TF-1 cells, a
GM-CSF/interleukin-3 (IL-3)-dependent cell line. The inhibi-
tion was speci¢c to GM-CSF since TF-1 cells continue to
grow in the presence of IL-3. We observed a factor in
BALF from IPAP patients that binds to and neutralizes
GM-CSF. The role of the factor in the pathogenesis of
IPAP is discussed.
2. Materials and methods
2.1. Subjects
Eleven patients with IPAP, two patients with secondary PAP, and
10 control subjects underwent bronchoalveolar lavage. The diagnosis
of PAP was con¢rmed by biochemical analysis of BALF and histo-
pathological ¢ndings of lung biopsy. IPAP patients demonstrated no
underlying disease including hematological disorders, infectious dis-
eases, or toxic inhalation. The two patients with secondary PAP had
chronic myelogenous leukemia. Written informed consent to partici-
pate in the study was obtained from all subjects.
2.2. Bronchoalveolar lavage £uid
BALF was centrifuged at 1000Ug for 15 min. The supernatant was
then centrifuged at 40 000Ug for 60 min. The supernatant was de¢ned
as ‘the BALF’. Protein concentration of the BALF was measured by
the method of Bradford [14] using the Bio-Rad Protein Assay (Bio-
Rad, Hercules, CA, USA) according to the manufacturer’s instruc-
tion.
2.3. Cytokines and antibodies
Recombinant human (rh) GM-CSF (speci¢c activity 2.25U108 U/
mg) was kindly provided by Kirin Brewery Co. Ltd. (Takasaki,
Japan), rhIL-3 was purchased from RpD (Minneapolis, MN,
USA). Rat anti-hGM-CSF monoclonal antibody 23B6 [15] was kindly
provided by Dr. T. Kitamura (The Institute of Medical Science, The
University of Tokyo, Tokyo, Japan). Peroxidase labeled anti-hGM-
CSF polyclonal antibody was purchased from RpD Systems and 125I-
Bolton Hunter labeled rhGM-CSF from NEN Life Science Products
(Boston, MA, USA).
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2.4. Preparation of human monocytes and TF-1 cells
Peripheral blood mononuclear cells (PBMC) were obtained from
healthy donors by Ficoll/Paque (Pharmacia Biotech, Uppsala, Swe-
den) density gradient centrifugation, resuspended in RPMI 1640 me-
dium (Nissui, Tokyo, Japan) supplemented with 10% heat inactivated
fetal calf serum (FCS). PBMC were incubated for 15 min at 37‡C in
250 ml tissue culture £asks (Falcon, Franklin Lakes, NJ) coated with
10% human AB serum in PBS. Non-adherent cells were removed by
vigorous washing with PBS and adherent cells were collected by gentle
scraping using a cell scraper (Sumitomo Bakelite, Tokyo, Japan) after
incubation with 0.05% trypsin/0.53 mM EDTA for 10 min at 37‡C. At
least 98% of the adherent cells were monocytes by morphology and
non-speci¢c esterase staining. The viability of cells was determined by
the trypan blue dye exclusion. TF-1 is a cell line dependent on GM-
CSF or IL-3 [16]. It was kindly provided by Dr. Kitamura (The
Institute of Medical Science, The University of Tokyo, Tokyo, Japan)
and maintained in RPMI 1640, 10% FCS, 10 ng/ml GM-CSF at 37‡C
in an atmosphere of humidi¢ed air containing 5% CO2. Before use,
TF-1 cells were washed three times in RPMI 1640 and 10% FCS
without GM-CSF.
2.5. Cell growth
Cell growth was evaluated by the MTT assay (3-[4,5-dimethylthia-
zol-2-yl]-2,5 diphenyl tetrazolium bromide; Sigma, St. Louis, MO,
USA) [17]. Brie£y, 5 Wg/ml of MTT was added to each well and
incubated for 2 h. After formation of formazan crystal by viable cells,
100 Wl of isopropanol/HCl was added to dissolve the crystals. The
absorbance was measured at 550 nm using a microplate spectropho-
tometer. Monocytes (1U104/well) or TF-1 cells (2U104/well) were
incubated for 3 days in a 96-well microplate (Falcon, Franklin Lakes,
NJ, USA) with various concentrations of GM-CSF or IL-3 (0, 0.625,
1.25, 2.5, 5, and 10 ng/ml) and the BALF from a PAP patient or a
control subject (0, 12.5, 25, 50 and 100 Wg/ml). The cells were ob-
served under a phase-contrast microscope (Diaphot 300; Nikon, To-
kyo, Japan).
2.6. 125I-GM-CSF receptor binding assays
The binding assay of GM-CSF to the receptor was performed as
previously described [18]. Brie£y, TF-1 cells (5U105) were suspended
in 1 ml of RPMI 1640 medium with 150 pM of 125I-GM-CSF and
various concentration of the BALF (0, 15.6, 31.3, 62.5, 125 and
250 Wg/ml) from an IPAP patient for 90 min at 15‡C. As a back-
ground reaction, the same reaction mixture was incubated with a
1000-fold excess amount of cold GM-CSF. The cell suspensions
were centrifuged at 250Ug for 5 min to remove unbound 125I-GM-
CSF from the cells, washed three times with cold PBS, and the radio-
activity incorporated into the cells was measured by a Q counter Wiz-
zard 1470 (Wallac, Turku, Finland). In some experiments, the recep-
tor binding assays were performed after TF-1 cells (1U106/ml) were
preincubated with 250 Wg/ml of IPAP-BALF or PBS at 15‡C for
90 min, washed with cold PBS three times.
2.7. Enzyme-linked immunosorbent assay (ELISA)
Percent binding inhibition of monoclonal anti-GM-CSF antibody
(23B6) to GM-CSF by the BALF was measured with the ELISA
system. A micro-ELISA plate (Nunc, Roskilde, Denmark) was coated
overnight at 4‡C with 100 Wl of 0.5 Wg/ml anti-hGM-CSF monoclonal
antibody. After washing ¢ve times with PBS, the plate was treated
with a blocking reagent (Stabilicoat; BSI Corp., Eden Prairie, MN,
USA) at room temperature for 1 h. After removal of the blocking
reagent, 50 Wl of 25 ng/ml GM-CSF and 50 Wl of various protein
concentrations of the BALF (0, 62.5, 125, 250, 375 and 500 Wg/ml)
from PAP patients or normal subjects were incubated in wells at room
temperature for 2 h. After washing with PBS, a peroxidase labeled
anti-hGM-CSF polyclonal antibody was added to each well and the
mixture was incubated at 37‡C for 1 h. Color development was per-
formed using TMB solution (Color Reagents; RpD, Minneapolis,
MN, USA). The absorbance was measured using a microplate spec-
trophotometer Model 3550 (Bio-Rad, Hercules, CA, USA). TNFK,
IL-6 and MCP-1 were assayed with corresponding commercial assay
kits (TNFK and MCP-1, RpD Systems, Minneapolis, MN, USA; IL-
6, Biosource, Camarillo, CA, USA). The percent inhibition was cal-
culated with the following equation:
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Fig. 1. The growth inhibition of TF-1 or monocytes by the BALF from a PAP patient. The horizontal axis is the concentration of BALF pro-
tein. (a: TF-1 incubated with GM-CSF; b: monocytes incubated with GM-CSF; c: TF-1 incubated with IL-3; d: monocytes incubated with
IL-3). The vertical axis is the activity of viable cells examined by the MTT assay. Cells were incubated with various concentration of GM-CSF
or IL-3 (10 ng/ml: b ; 5: R ; 2.5: F ; 1.25: 8 ; 0.625: S ; 0: a). In both TF-1 and monocytes, the MTT uptake was signi¢cantly decreased as
the protein concentration of the BALF increased (a and b). In contrast, the BALF did not a¡ect the bioactivity of IL-3 in both TF-1 and
monocytes at all (c and d).
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2.8. Cross-linking studies
IPAP-BALF (500 Wg/ml) or the BALF from a normal subject was
incubated with 125I-GM-CSF (6 nM) in the binding bu¡er (25 mM
HEPES, pH 7.4, 150 mM NaCl, 10 mM KCl, 10 mM CaCl2) for
90 min at room temperature. As a background reaction, the same
reaction mixture contained a 100-fold excess amount of cold GM-
CSF together with IPAP-BALF. The cross-linking reaction was per-
formed with 300 WM of disuccinimidyl suberate (DSS: Pierce, Rock-
ford, IL, USA) at 4‡C for 15 min. The reaction was quenched by
adding 1 ml of quenching bu¡er (50 mM Tris-HCl pH 8.0, 15 mM
NaCl, 2 mM EDTA). The mixtures were electrophoresed with SDS-
polyacrylamide gel. The gel was dried and exposed to X-ray ¢lm.
3. Results
3.1. Inhibition of GM-CSF-dependent cell growth with
IPAP-BALF
We found that IPAP-BALF inhibited the growth of mono-
cytes and TF-1 cells when they were cultured with 1 ng/ml of
GM-CSF (Fig. 1a,b). The inhibition was dependent on the
concentration of the BALF added to the culture medium
and was not observed when these cells were cultured with
IL-3 instead of GM-CSF (Fig. 1c,d). BALF from a normal
subject did not inhibit the growth of these cells cultured with
1n g/ml of GM-CSF. BALF from IPAP patients also reduced
the viability of TF-1 cells as measured by suppression of MTT
uptake. All of the 11 IPAP-BALF demonstrated this e¡ect
but the BALF from secondary PAP patients and normal sub-
jects did not reduce the viability of TF-1 cells (Fig. 2).
TF-1 cells and blood monocytes were similar. As shown in
Fig. 3, the viability of monocytes cultured with 1 ng/ml of
GM-CSF and 100 Wg/ml of IPAP-BALF for 72 h was less
than 5%, whereas the viability was higher than 95% when
monocytes were cultured with 1 ng/ml of GM-CSF and
100 Wg/ml of the control BALF. These results indicate that
the IPAP-BALF is not toxic to these cells but instead specif-
ically inhibits the bioactivity of GM-CSF.
3.2. IPAP-BALF inhibits GM-CSF binding to TF-1 cells and
to anti-GM-CSF antibody
We examined binding of 125I-GM-CSF to TF-1 cells in the
presence of IPAP-BALF to clarify whether loss of GM-CSF
bioactivity is due to inhibition of cytokine/receptor interac-
tion. As shown in Fig. 4a, GM-CSF binding to TF-1 cells
was inhibited with the increased concentrations of BALF pro-
tein (Fig. 4a). The inhibition was not observed in BALF from
a normal subject. This result indicates that the inhibition of
bioactivity is due to blocking of cytokine/receptor interaction.
Preincubation of TF-1 with IPAP-BALF did not in£uence
binding of 125I-GM-CSF to the cells ; the binding pro¢le of
125I-GM-CSF to TF-1 cells preincubated with either the
BALF or medium alone showed the same pattern (Fig. 4b).
These results indicate that the IPAP-BALF does not interfere
with the receptor directly.
We next examined binding of GM-CSF to a monoclonal
antibody 23B6 speci¢c for GM-CSF. We found that IPAP-
BALF from all 11 patients interfered with the binding of GM-
CSF to its antibody using a sandwich ELISA system. The
percent inhibition was dose-dependent (Fig. 5). BALF from
two secondary PAP patients or three controls showed no ef-
fect on binding of GM-CSF to antibody 23B6 even at a high
protein concentration level up to 500 Wg/ml. The IPAP-BALF
did not a¡ect binding of other cytokines including TNF, IL-6,
and MCP-1 to corresponding antibodies (data not shown).
Thus, these data suggest that the BALF speci¢cally inhibits
binding of GM-CSF to the monoclonal antibodies and recep-
tors. This raises the possibility that the loss of GM-CSF bio-
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Fig. 3. Phase-contrast micrographs (low-power views, U25) of
monocytes incubated with 1 ng/ml of GM-CSF and 100 Wg/nl of
the BALF from an IPAP patient (a) or a control subject (b).
Fig. 2. Growth inhibition of TF-1 by the BALF from 10 controls,
11 IPAP patients, and two secondary PAP patients. The vertical
axis is the optical density of formazan at 550 nm which corresponds
to the activity of viable cells examined by the MTT assay. Cells
were cultured with 1 ng/ml of GM-CSF and 100 Wg/ml of the
BALF in protein contents for 3 days.
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activity is due to binding and neutralization of the cytokine
itself.
3.3. Occurrence of 125I-GM-CSF binding factor(s) in
IPAP-BALF
We assayed for GM-CSF binding activity by cross-linking
125I-GM-CSF to IPAP-BALF followed by SDS-PAGE size
separation (Fig. 6). IPAP-BALF contained a 125I-GM-CSF
binding activity which produced two radioactive bands mi-
grating at 39 and 41 kDa. Excess unlabeled GM-CSF signi¢-
cantly reduced the intensity of the bands and BALF from a
control subject did not form these complexes. These data
demonstrate that a factor in IPAP-BALF speci¢cally binds
to GM-CSF.
4. Discussion
In the present study, we have demonstrated the existence of
a factor in the lung of IPAP patients that binds speci¢cally to
GM-CSF and neutralizes its bioactivity. IPAP-BALF inhib-
ited the growth of blood monocytes and TF-1 cells, a GM-
CSF/IL-3-dependent cell line. This inhibition was not due to
non-speci¢c toxicity of the IPAP-BALF since TF-1 cells sup-
plemented with IL-3 continued to grow in the presence of
IPAP-BALF. IPAP-BALF also prevented GM-CSF binding
to TF-1 cells and to a monoclonal antibody speci¢c for GM-
CSF. Preincubation of TF-1 cells with IPAP-BALF followed
by a medium change did not prevent GM-CSF binding sug-
gesting that the factor expressed in IPAP did not bind the
GM-CSF receptor. Cross-linking of radiolabeled GM-CSF
to IPAP-BALF directly demonstrated that the factor ex-
pressed in IPAP bound GM-CSF. The inhibition of bioactiv-
ity or antibody binding was observed only in IPAP patients
but not in secondary PAP patients or normal subjects, sug-
gesting that this factor is involved in the pathogenesis of
IPAP. Because BALF is a 100^500-fold diluted £uid of alveo-
lar surfactant [19], GM-CSF binding activity in the lung of
IPAP is estimated to be 100^500 times stronger than that
observed in the BALF.
Previously, soluble GM-CSF receptor K chain has been
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Fig. 6. Cross-linking of 125I-GM-CSF to BALF followed by SDS-
PAGE. Lane a: 125I-GM-CSF without the BALF; lane b: 125I-GM-
CSF with the BALF from a normal subject; lane c: 125I-GM-CSF
with the BALF from an IPAP patient; lane d: 125I-GM-CSF with
the BALF from an IPAP patient with excess unlabeled GM-CSF.
The bands at 39 and 41 kDa are due to a complex of 125I-GM-CSF
and a GM-CSF binding factor expressed in BALF from IPAP pa-
tients.
Fig. 5. Percent inhibition of the binding of monoclonal anti-GM-
CSF antibody (23B6) to GM-CSF by the BALF from 11 idiopathic
PAP patients (b), two secondary PAP (R), and three control sub-
jects (b). The horizontal axis is the concentration of protein in
BALF. The vertical axis is the percent inhibition of binding as de-
scribed in Section 2.
Fig. 4. a: Competitive inhibition of 125I-GM-CSF binding to TF-1
cells by IPAP-BALF. TF-1 cells (5U105) were incubated with 125I-
GM-CSF (70 pM) and various concentration of IPAP-BALF (b) or
250 Wg/ml of BALF from a control (a). 125I-GM-CSF binding to
TF-1 was inhibited with increased concentrations of the BALF pro-
tein. The data are shown as the mean þ S.D. b: The e¡ect of prein-
cubation of TF-1 cells with 100 Wg/ml of IPAP-BALF on 125I-GM-
CSF binding to the cells (2U105). After TF-1 cells (1U106/ml) were
preincubated with 250 Wg/ml of IPAP-BALF (b) or PBS (a) at
15‡C for 90 min, and washed with cold PBS three times, the cells
were incubated with various concentrations of 125I-GM-CSF
(0^5 nM) at 15‡C for 90 min.
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reported to be a speci¢c ligand that bind to GM-CSF [20^22].
It is possible that soluble GM-CSF receptor may be overex-
pressed in the lungs of IPAP patients and inhibits the binding
of GM-CSF to the receptor. However, our preliminary data
showed that anti-GM-CSF receptor K chain neutralizing anti-
body failed to abrogate the GM-CSF binding activity (unpub-
lished data). Thus, soluble GM-CSF receptor is unlikely to be
a candidate for the GM-CSF binding factor in the lung of
IPAP.
Mice de¢cient for GM-CSF or its receptor develop PAP
[11,12]. Surfactant proteins were all signi¢cantly increased in
BAL from both knockout mice compared with wild-type
mice, and their lungs contained eosinophilic acellular material
in alveolar spaces accompanied by increased tubular myelin.
Correction of PAP in the receptor knockout mouse was ac-
complished by bone marrow transplantation from wild-type
mice to Lc-de¢cient mice demonstrating the central role of
AM in this disorder [13]. Furthermore, Hu¡mann and col-
leagues recently reported that pulmonary epithelial expression
of GM-CSF using an SP-C-GM-CSF construct in GM-CSF-
de¢cient mice corrected PAP [23]. These model systems sup-
port a causal role for the GM-CSF neutralizing activity de-
scribed in this investigation in the pathogenesis of human
IPAP.
GM-CSF is a cytokine that increases complement- and
antibody-mediated phagocytosis, enhances leukocyte chemo-
taxis, and augments antitumor immunity in macrophages. The
lung produces GM-CSF constitutively and epithelial lining
£uid in the alveolar spaces contains an approximately 100-
fold higher concentration of GM-CSF than the plasma [24].
However, the true functions of GM-CSF in the lung are un-
known. Previously, we demonstrated that GM-CSF in the
lung promotes the proliferation of AM [25] but the number
of AM is normal in the GM-CSF-de¢cient mouse. Thus, it is
likely that GM-CSF does not contribute to the proliferation
of AM in the steady state but instead modulates AM func-
tion. AM from GM-CSF knockout mice are ¢lled with sur-
factant-like material. This phenotype improves after therapeu-
tic lavage [26,27]. The data from the mouse model suggest
that in the absence of GM-CSF, AM have a defect of surfac-
tant catabolism. Therefore, the neutralization of GM-CSF
bioactivity observed in this study is a plausible explanation
of the pathogenesis of human primary PAP.
AM from GM-CSF knockout mice also have de¢cient che-
motaxis. Because AM are important immune cells for ¢rst line
defense in the lung, this may increase susceptibility to infec-
tions. In fact, IPAP is sometimes complicated by pulmonary
opportunistic infections, particularly nocardiosis, Pneumocys-
tis carinii pneumonia, and aspergillosis [28].
Wong et al. recently reported that mRNA of the GM-CSF
gene in BAL cells from an IPAP patient is induced by lip-
opolysaccharide (LPS) stimulation in vitro, but that GM-CSF
protein production was undetectable when the cells were in-
cubated with or without LPS [29]. They also demonstrated
that exaggerated release of IL-10 from PAP lung may sup-
press the production of GM-CSF. As IL-10 is known to sup-
press GM-CSF production at the transcriptional level by
blocking NF-UB activation, this hypothesis does not clearly
explain why mRNA of GM-CSF in the BAL cells is inducible
but the production of protein is blocked. In contrast, as dem-
onstrated in our study, the bioactivity of GM-CSF is blocked
in the lungs of patients with IPAP by a factor that binds to
GM-CSF. Further characterization of this factor will greatly
contribute to the elucidation of not only the pathogenesis
of IPAP but also the true function(s) of GM-CSF in the
lung.
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